1 Year Total Returns (Daily) Chart

View 1 Year Total Returns (Daily) for QURE.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View 1 Year Total Returns (Daily) Chart
Start Trial

Historical 1 Year Total Returns (Daily) Data

View and export this data back to 2015. Start Trial.
Date Value
September 29, 2026 -58.74%
September 28, 2026 -27.99%
September 25, 2026 -27.39%
September 24, 2026 -19.33%
September 23, 2026 213.0%
September 22, 2026 227.4%
September 21, 2026 219.5%
September 18, 2026 198.5%
September 17, 2026 211.4%
September 16, 2026 193.6%
September 15, 2026 190.5%
September 14, 2026 172.6%
September 11, 2026 162.8%
September 10, 2026 154.4%
September 09, 2026 163.0%
September 08, 2026 162.1%
September 04, 2026 151.0%
September 03, 2026 158.1%
September 02, 2026 171.8%
September 01, 2026 193.1%
August 31, 2026 198.1%
August 28, 2026 199.6%
August 27, 2026 214.7%
August 26, 2026 222.7%
August 25, 2026 228.3%
Date Value
August 24, 2026 202.3%
August 21, 2026 211.1%
August 20, 2026 215.8%
August 19, 2026 218.1%
August 18, 2026 202.6%
August 17, 2026 196.5%
August 14, 2026 208.1%
August 13, 2026 222.3%
August 12, 2026 215.6%
August 11, 2026 218.7%
August 10, 2026 246.8%
August 07, 2026 245.1%
August 06, 2026 236.2%
August 05, 2026 216.0%
August 04, 2026 217.2%
August 03, 2026 221.7%
July 31, 2026 213.4%
July 30, 2026 191.8%
July 29, 2026 192.9%
July 28, 2026 144.7%
July 27, 2026 152.9%
July 24, 2026 156.2%
July 23, 2026 156.4%
July 22, 2026 183.4%
July 21, 2026 176.5%

Total Return Definition

The Total return is the change in price over a specific period of time that includes dividends and distributions paid.

Read full definition.

1 Year Total Returns (Daily) Range, Past 5 Years

View 1 Year Total Returns (Daily) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

1 Year Total Returns (Daily) Benchmarks

View 1 Year Total Returns (Daily) Benchmarks
Start Trial
Kymera Therapeutics, Inc. 88.91%
Sarepta Therapeutics, Inc. -0.96%
Twist Bioscience Corp. 589.4%
GRAIL, Inc. 132.4%
Arrowhead Pharmaceuticals, Inc. 96.12%